N/A N=34,100 Transatlantic Active Surveillance on Cardiovascular Safety of NuvaRing (TASC)
Contraception
Primary: Number of Participants With Venous Thromboembolism (VTE) — 19; 26; 21 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=12 Study of Kuvan Treatment in Adults With GTPCH Deficiency
GTP Cyclohydrolase Deficiency
Primary: Change in BH4 Levels in Cerebral Spinal Fluid — 6; 10.7; 5.3; 13.2 nmol/L
Phase 4 N=50 Effects of LDX on Functioning of College Students With ADHD
Attention-deficit/Hyperactivity Disorder
Primary: Conners Adult ADHD Rating Scale - Short Version (CAARS) — 50.59; 46.86; 47.32; 45.36 T score — p=<0.001
N/A N=13 Evaluation of Respiratory Heast Loss as a Physiologic Patient Monitor for Acute Care Medicine
Respiratory Heat Loss
Primary: Evaluation of Respiratory Heat Loss as a Physiologic Patient Monitor for Acute Care Medicine — 29.7 Joules per minute
Phase 2 N=169 Efficacy and Safety of S-equol on Vasomotor Symptoms in Menopausal Patients
Menopause
Primary: Mean Change in Frequency of Moderate to Severe Vasomotor Symptoms (MSVS) Baseline at Week 4 (2-week Period) — 73.5; 69.5; 70.4; 67.9 Number of MSVS/2 weeks — p=0.5730
Phase 2 N=32 Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody
Lymphoma, Non-Hodgkin
Primary: Number of Participants With Complete Response and Confirmed Complete Response — 8; 8 Participants
Phase 3 N=5,883 RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial
Atrial Fibrillation
Primary: Major Bleeding, Annualized Rate of Subjects With Major Bleeds — 2.79; 3.59 percentage of subject-years — p=0.0055
Phase 3 N=660 Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Daily Insulin Dose at Week 24 — 19.0; 23.8 International Units (IU) — p=0.009
Phase 2 N=68 Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)
Rheumatoid Arthritis
Primary: Short Term Period: Steady-state Trough Serum Concentration (Cmin) of Abatacept Following Weekly Subcutaneous Dosing in Participants With Active Rheumatoid Arthritis…
N/A N=4,208 Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Rheumatoid Arthritis
Primary: Change From Baseline in Disease Activity Score (DAS) 28 — -1.5; -1.8; -1.9; -2.0 units on a scale
Phase 2 N=25 Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma
Lymphoma, Mantle-Cell
Primary: Number of Participants With the Indicated Unconfirmed Response (Complete Response, Complete Response Unconfirmed, and Partial Response) — 14; 2; 5 Participants
Phase 3 N=12 Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)
Rheumatoid Arthritis
Primary: Percent Change From Baseline in Synovial TNFa, CXCL13, IL-8, IL-6, IL-1b, IL-10, IP-10, BCL3, CD3E, DUSP4, FOXP3, CD79A, CD138, MMP-3, and MMP-1 After 12 Weeks of…
Phase 4 N=296 The Impact of Osmotic Release Oral Delivery System Methylphenidate (OROS MPH) Upon Family of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Disorder With Hyperactivity
Primary: Mean Change From Baseline in Swanson, Nolan and Pelham-Fourth Edition (SNAP-IV) Rating Scale (Parents) Score at Week 2 — 1.7; 1.4; 1.3; -0.4 Units on a scale
Phase 2 N=29 Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation
Graft Versus Host Disease · GVHD
Primary: Incidence of Grade II-IV Acute GVHD (aGVHD) Developing by Day 100 Following Non-myeloablative PBSC Transplantation Using Tacrolimus and Sirolimus. — 5 participants
N/A N=411 Triathlon® Cruciate Retaining (CR) Total Knee System Outcomes Study
Arthroplasty, Replacement, Knee
Primary: Active Range of Motion — 119.2 Degrees